Recent Price Movement and Market Context
On the trading day, Sanofi Consumer Healthcare’s shares touched an intraday low of Rs 4,285, representing a 2.24% drop from the previous close. The stock has been on a downward trajectory for two consecutive sessions, cumulatively losing 3.27% in returns during this period. This decline outpaced the Pharmaceuticals & Biotechnology sector’s performance, with the stock underperforming the sector by 0.92% on the day.
Sanofi Consumer is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum. This technical positioning contrasts with the broader market, where the Sensex opened lower at 84,022.09 points, down 0.19%, but remained only 2.36% shy of its 52-week high of 86,159.02. Mid-cap stocks led the market gains, with the BSE Mid Cap index rising by 0.07% on the same day.
Valuation and Financial Performance
Sanofi Consumer Healthcare India Ltd’s valuation metrics have come under scrutiny amid the recent price decline. The company’s Price to Book Value stands at a high 39.1, reflecting a very expensive valuation relative to its book value. Despite a robust Return on Equity (ROE) of 83.6%, the stock’s performance has not aligned with these efficiency metrics.
Over the past year, the stock has delivered a negative return of 11.48%, significantly lagging behind the Sensex’s positive 8.36% gain. This underperformance extends to longer time frames as well, with the stock trailing the BSE500 index over the last three years, one year, and three months. Profitability has also seen a decline, with reported profits falling by 27% over the same period, contributing to the downward pressure on the share price.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Operational and Financial Highlights
Despite the recent price weakness, Sanofi Consumer Healthcare maintains several positive operational metrics. The company exhibits high management efficiency, with a ROE of 76.98% noted in recent assessments. Its debt profile remains conservative, with an average Debt to Equity ratio of zero, indicating a debt-free capital structure that reduces financial risk.
Long-term growth trends remain healthy, with net sales expanding at an annual rate of 95.70% and operating profit growing at 83.94%. The company’s quarterly results for September 2025 were notable, with net sales reaching a record Rs 233.90 crore, profit before tax excluding other income at Rs 81.10 crore, and profit after tax at Rs 62.90 crore, all marking the highest levels recorded in recent quarters.
Shareholding and Market Sentiment
Institutional investors hold a significant stake in Sanofi Consumer Healthcare, with 20.15% of shares owned by entities with greater analytical resources and long-term perspectives. This level of institutional holding often reflects confidence in the company’s fundamentals despite short-term price fluctuations.
Considering Sanofi Consumer Healthcare India Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Technical and Market Grade Assessment
Sanofi Consumer Healthcare India Ltd currently holds a Mojo Score of 43.0 and a Mojo Grade of Sell, reflecting a downgrade from its previous Hold rating as of 28 Oct 2025. The market capitalisation grade stands at 3, indicating a mid-tier market cap classification. The stock’s day change was negative at -1.03%, consistent with the recent downward trend.
The stock’s 52-week high was Rs 5,954, highlighting the extent of the recent decline to the current low of Rs 4,285. This represents a significant retracement from its peak, underscoring the challenges faced in maintaining previous valuation levels.
Sector and Market Comparison
While Sanofi Consumer Healthcare has experienced a decline, the broader Pharmaceuticals & Biotechnology sector has shown mixed performance. The Sensex, although opening lower, remains close to its 52-week high, supported by mid-cap strength. This divergence suggests that the stock’s price movement is more company-specific rather than purely sector-driven.
In summary, Sanofi Consumer Healthcare India Ltd’s fall to a 52-week low of Rs 4,285 reflects a combination of valuation recalibration, profit contraction, and technical weakness. The company’s strong operational metrics and institutional backing provide context to the current price environment, which remains under pressure amid broader market dynamics.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
